- Home
- PDD vs AMGN Comparison
PDD vs AMGN Comparison
Compare PDD & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDD
- AMGN
- Stock Information
- Founded
- PDD 2015
- AMGN 1980
- Country
- PDD Ireland
- AMGN United States
- Employees
- PDD N/A
- AMGN N/A
- Industry
- PDD Business Services
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PDD Consumer Discretionary
- AMGN Health Care
- Exchange
- PDD Nasdaq
- AMGN Nasdaq
- Market Cap
- PDD 162.9B
- AMGN 156.2B
- IPO Year
- PDD 2018
- AMGN N/A
- Fundamental
- Price
- PDD $96.51
- AMGN $288.18
- Analyst Decision
- PDD Buy
- AMGN Buy
- Analyst Count
- PDD 12
- AMGN 21
- Target Price
- PDD $137.83
- AMGN $323.62
- AVG Volume (30 Days)
- PDD 10.4M
- AMGN 3.2M
- Earning Date
- PDD 05-27-2025
- AMGN 05-01-2025
- Dividend Yield
- PDD N/A
- AMGN 3.30%
- EPS Growth
- PDD 22.63
- AMGN 56.16
- EPS
- PDD 9.23
- AMGN 10.94
- Revenue
- PDD $55,494,551,527.00
- AMGN $34,126,000,000.00
- Revenue This Year
- PDD $21.17
- AMGN $7.62
- Revenue Next Year
- PDD $18.31
- AMGN $1.88
- P/E Ratio
- PDD $10.45
- AMGN $26.34
- Revenue Growth
- PDD 35.67
- AMGN 15.56
- 52 Week Low
- PDD $87.11
- AMGN $253.30
- 52 Week High
- PDD $155.67
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- PDD 32.38
- AMGN 58.41
- Support Level
- PDD $97.32
- AMGN $269.10
- Resistance Level
- PDD $101.16
- AMGN $276.90
- Average True Range (ATR)
- PDD 3.82
- AMGN 5.90
- MACD
- PDD -2.51
- AMGN 2.48
- Stochastic Oscillator
- PDD 4.58
- AMGN 97.70
About PDD PDD Holdings Inc.
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. PDD aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from the increased productivity and new opportunities. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.